[
    [
        {
            "time": "2018-01-02",
            "original_text": "Abbvie settles Humira patent disputes with Novartis unit",
            "features": {
                "keywords": [
                    "Humira",
                    "patent",
                    "disputes",
                    "Novartis",
                    "settles"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes",
            "features": {
                "keywords": [
                    "Sandoz",
                    "AbbVie",
                    "Humira",
                    "patent",
                    "resolution"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "AbbVie stock ticks higher as Humira patent dispute with Novartis resolved",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock",
                    "Humira",
                    "patent",
                    "resolved"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Wall Street Analysts See Upside Potential of 3.9% in TEVA",
            "features": {
                "keywords": [
                    "Wall Street",
                    "Analysts",
                    "TEVA",
                    "upside",
                    "potential"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales",
            "features": {
                "keywords": [
                    "Incyte",
                    "Jakafi",
                    "demand",
                    "strong",
                    "label",
                    "expansion"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing",
            "features": {
                "keywords": [
                    "Teva",
                    "FDA",
                    "Committee",
                    "Rituxan",
                    "Biosimilar",
                    "Nod"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Novartis Presents Data on Multiple Sclerosis Drug Gilenya",
            "features": {
                "keywords": [
                    "Novartis",
                    "Gilenya",
                    "Multiple Sclerosis",
                    "Data"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Analysts’ Estimates and Ratings for Novartis in October",
            "features": {
                "keywords": [
                    "Analysts",
                    "Estimates",
                    "Ratings",
                    "Novartis"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 6,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "A Look at the Performance of Novartis’s Alcon",
            "features": {
                "keywords": [
                    "Novartis",
                    "Alcon",
                    "Performance"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 6,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        }
    ]
]